Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  samarium Sm 153 lexidronam pentasodium
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-15 of 15 for your search:
Start Over
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 0517, CDR0000491233, NCI-2009-00727, NCT00365105
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
Phase: Phase II, Phase I
Type: Supportive care
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: NYM-354, NCT00374751
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000546736, P30CA015083, MC0585, 1586-05, MAYO-MC0585, MAYO-IRB-1586-05, NCT00478075
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000546769, P30CA015083, MC048B, 261-05, MAYO-MC048B, MAYO-IRB-261-05, NCT00482378
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000582552, P30CA015083, MC9981, 1046-99, MAYO-MC9981, NCT00602706
Phase II Study of Samarium Sm 153 Lexidronam Pentasodium (153Sm-lexidronam) in Combination with Total Androgen Blockade in Patients with Stage D2 Prostate Carcinoma (Summary Last Modified 06/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CYTOGEN-424Sm17, NCI-V97-1255
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 13 to 50
Sponsor: NCI, Other
Protocol IDs: J0347 CDR0000447134, JHOC-J0347, JHOC-03090802, J0347, NCT00245011
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 070106, 07-C-0106, NCI-07-C-0106, 7678, NCT00450619
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Phase: Phase II
Type: Behavioral study, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2006-0349, NCI-2010-00573, NCT00429507
Phase I Study of 153Sm-EDTMP in Children with Refractory Malignancies and Painful Osseous Lesions (Summary Last Modified 07/97)
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: over 5 to 25
Sponsor: NCI
Protocol IDs: NCI-95-C-0113A
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000479712, ONCOTHER-20051780, ONCOTHER-424Sm35, CYTOGEN-ONCOTHER-20051780, NCT00316940
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 02C.172, 2001-114, NCT00328614
Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: J0467, 04-09-03-03, NCT00559429
Start Over